|
|
Profile
|
Delegates :
Hideaki Sato |
|
Incorporated :
December 18 , 2017 |
Paid in Capital :
90 Million yen |
Employees :
23 人 |
Address :
9F C907, Osaka University Techno Alliance C Building 2-8 Yamadaoka, Suita, Osaka, Japan OSAKA
〒565-0871
|
TEL/FAX :
+81-6-6170-1228 / +81-6-6170-2207 |
URL：
https://luxnabiotech.co.jp/ |
Attachment :
|
Mission/Background :
Luxna Biotech was established to contribute to the medical treatments of patients suffering from diseases through the creation of nucleic acid drugs that accelerate the practical application of nucleic acid drugs using proprietary technology. With the corporate philosophy of "bring “light” to patients who are fighting a disease and to those who support them," Luxna Biotech promotes collaborative research with pharmaceutical companies and in-house development of seeds from academia.
|
|
Technology & Business
|
1. XNAs Technology exclusively licensed from Osaka University
We have identified three innovative bridged nucleic acids (AmNA, scpBNA and GuNA) with different characteristics and 5'-CP, a type of DNA with a modified 5' position. The bridged nucleic acids have improved nuclease resistance and binding affinity to targeted mRNA, and in addition to reduced hepatotoxicity, are expected to alter the pharmacokinetics of nucleic acid drugs. In addition, 5'-CP has high affinity with bridged nucleic acids and is expected to reduce neurotoxicity.
2. superior sequence design technology
By utilizing the XNAs technology from Osaka University and the National Institute of Biomedical Innovation, we have established an ASO drug discovery platform (LuxiAP) that enables rapid sequence design, synthesis, selection of ASO candidate sequences, and activity evaluation, resulting in a wider range of sequence candidates for targets and improved safety and efficacy.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Technology alliance: XNAs Technology (AmNA, scpBNA, GuNA, 5’-CP)
|
Discovery
|
Exclusive licensing of XNAs technology on a target gene basis, Supply monomers to licensees
|
Obtaining domestic and international technology alliance partners ,Conduct clinical trials at licensed partners
|
Collaborative research using proprietary technologies: LuxnaAP
|
Discovery
|
Collaborative research (drug discovery, optimization of candidate compounds, etc.) utilizing XNAs technology and LuxiAP on a
|
Attracting new collaborators in Japan and overseas, Achieve milestones in ongoing collaborations and transition to licensing
|
Pipeline: Spinal Cord Injury: SCI
|
Preclinical
|
ASO targeting the CSGalNAcT1 gene, In-house development of the NHP study under the supports of AMED CiCLE
|
Co-development or finding a licensing partner after the NHP efficacy trial
|
Pipe line: Drug-induced hearing loss
|
Discovery
|
ASO targeting a specific gene, Undergoing proof-of-concept
|
After proof of concept, co-development or finding a licensing partner
|
|
|
|
|
|
Highlights
|
Awards and Capital Increase
Dec. 2023 Selected as Zebra by Kansai Innovation Initiative
April 2023 Selected as a J-Startup target company
December 2021 Series B round completed
Technology- and business
Apr. 2024 Expansion of alliance with Servier
Dec. 2023 Tohoku University begin collaborative research for ASOs for the treatment of hearing loss
Feb. 2022 Exclusive license agreement with Takeda Pharmaceutical for XNAs technology
|
|
Hot news
|
XNAs technology also contributes to reduction of hepatotoxicity and neurotoxicity, improvement of affinity for target genes mRNA. In addition to Gapmer-type ASOs, we have also developed expertise for splicing switching oligonucleotides (SSOs).
The XNAs technology has been objectively evaluated.
|
|
Alliance strategy
|
We are looking for：
Companies with in-house nucleic acid drug discovery expertise and resources to utilize the XNAs technology.
ASO collaborators (drug discovery, optimization of candidate compounds, etc.) using the XNAs technology. We are also open to collaborations with companies that do not have the in-house expertise and resources.
Co-development or out-licensing partners for our pipelines for spinal cord injury and drug-induced hearing loss.
|
|
|